X4 PHARMACEUTIC. DL-001
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, an… Read more
Market Cap & Net Worth: X4 PHARMACEUTIC. DL-001 (48Q)
X4 PHARMACEUTIC. DL-001 (F:48Q) has a market capitalization of $29.13 Million (€28.38 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #25021 globally and #2744 in its home market, demonstrating a 2663.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying X4 PHARMACEUTIC. DL-001's stock price €4.90 by its total outstanding shares 5788740 (5.79 Million).
X4 PHARMACEUTIC. DL-001 Market Cap History: 2020 to 2025
X4 PHARMACEUTIC. DL-001's market capitalization history from 2020 to 2025. Data shows change from $31.49 Million to $29.13 Million (-8.99% CAGR).
X4 PHARMACEUTIC. DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how X4 PHARMACEUTIC. DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 48Q by Market Capitalization
Companies near X4 PHARMACEUTIC. DL-001 in the global market cap rankings as of March 19, 2026.
Key companies related to X4 PHARMACEUTIC. DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
X4 PHARMACEUTIC. DL-001 Historical Marketcap From 2020 to 2025
Between 2020 and today, X4 PHARMACEUTIC. DL-001's market cap moved from $31.49 Million to $ 29.13 Million, with a yearly change of -8.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €29.13 Million | +531.70% |
| 2024 | €4.61 Million | +2.11% |
| 2023 | €4.52 Million | -11.11% |
| 2022 | €5.08 Million | -55.70% |
| 2021 | €11.47 Million | -63.58% |
| 2020 | €31.49 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of X4 PHARMACEUTIC. DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.13 Million USD |
| MoneyControl | $29.13 Million USD |
| MarketWatch | $29.13 Million USD |
| marketcap.company | $29.13 Million USD |
| Reuters | $29.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.